IA Injection of Rejoint Gel and PRP in Patients With Unilateral Knee OA

Knee Osteoarthritis Clinical Trial

Official title:

A Randomized, Double-blind, Feasibility Study to Evaluate the Safety and Potential for Effectiveness of Intra-articular Injection of Rejoint Gel After Platelet-rich Plasma Administration in Patients With Unilateral Knee Osteoarthritis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04519047
• Other study ID #: 201812157DSA
• Status: Recruiting
• Phase: Phase 1
• Start date: August 13, 2020
• Est. completion date: December 31, 2021

Study information

• Verified date: August 2020
• Source: National Taiwan University Hospital
• Contact: Chueh-Hung Wu, MD, PhD
• Phone: +886223123456
• Email: nojred[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To assess the safety and tolerability of intra-articular Injection doses of Rejoint Gel after platelet-rich plasma administration in unilateral knee OA subjects.

Description:

This single-center, randomized, double-blind, feasibility study to evaluate the safety and potential for effectiveness of an intraarticular Injection of Rejoint Gel after platelet-rich plasma administration in patient with single knee OA, parallel-design study will enroll approximately eligible 30 subjects with single knee OA.

The subjects will be randomized (1:1) to receive 1 of 2 treatments below:

1. Treatment Group: Rejoint Gel, intra-articular injection, with platelet-rich plasma (PRP) in 2:1 volume ratio or

2. Control Group: Normal saline, intra-articular injection with PRP in 2:1 volume ratio Beginning on treatment period, subjects will receive a single treatment cycle of either 150 mg/ml Rejoint Gel or normal saline with PRP intra-articular injection twice for one month (Visit 3 and 4). Subjects will be followed to Visit 5, 6 and 7 for safety and potential for effectiveness assessments.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 31, 2021
• Est. primary completion date: December 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 45 Years to 80 Years

Eligibility

Inclusion criteria

1. Written informed consent before any study-specific procedure is performed;

2. Ages of 45~80 years old on the day of consent;

3. The patient is able to understand the nature of the study;

4. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2;

5. Patient was diagnosed as OA of single knee joint by American College of Rheumatology (ACR) criteria; [i.e, knee pain, and any one of the following: age> 45 years, crepitus, or morning stiffness<30 minutes in duration, or confirmed through radiographic X ray];

6. Knee WOMAC Pain Score (sum of five components) between 20 and 40 score, after 15 meters of walking pain;

7. Contralateral knee WOMAC Pain Score <15 score;

8. Never receiving intra-articular hyaluronic acid (HA) injections of the knee, or last received intra-articular HA more than 6 months;

9. Patient meets below conditions by blood test, kidney and liver function test :

White blood cell (WBC) count > 3,000/µL Absolute neutrophil count (ANC) = 1,500/µL Hemoglobin (Hb) = 9.0 g/dL Thrombocyte count > 50,000/µL Blood urea nitrogen (BUN) and serum Creatinine = 3X Upper Limit of Normal (ULN) Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) = 3 x ULN

Exclusion criteria

1. Known sensitivity to mPEG-PLGA hydrogel (Rejoint Gel);

2. Infection in the joint or surrounding skin;

3. Known Intra-articular neoplasm;

4. Inflammatory joint disease, OA in the hips, osteonecrosis, moderate to marked effusion from index knee;

5. Documented current positive synovial fluid culture;

6. Large knee circumference (>45 cm);

7. History of herpes zoster in the past 3 months;

8. Last receiving the treatment of immunosuppressants, anti-coagulants, Non-steroidal anti-inflammatory Drugs (NSAIDs), antidepressants 14 days prior to study randomization;

9. Planned knee surgery in the next 6 months or received knee surgery in the past 6 months;

10. Subject is receiving or is less than 28 days since ending other investigational device or drug;

11. Known full-thickness cartilage loss in index knee;

12. Documented fibromyalgia, or hemiparesis;

13. Evidence of signs or symptoms of a viral, bacterial, or fungal infection occur 14 days prior to the study treatment starts, per the assessment of the investigator;

14. Any major medical or psychiatric disorder that in the opinion of the investigator, might prevent the subject from completing the study or interfere with the interpretation of the study results, such as terminal diseases, malignant tumors, heart failure (NYHA II-IV), coronary arterial disease, uncontrolled hypertension, uncontrolled diabetes, peripheral arterial disease or dementia, might prevent the subject from completing the study or interfere with the interpretation of the study results;

15. Pre-menopausal females of childbearing potential not willing to use acceptable method(s) of birth control during treatment;

16. Female subject who is lactating or pregnant

Related Conditions & MeSH terms

• Knee Osteoarthritis
• Osteoarthritis
• Osteoarthritis, Knee
• PRP

Intervention

Biological:
• PRP
Beginning on treatment period, subjects will receive either Rejoint Gel or normal saline with PRP intra-articular injection twice for one month (Visit 3 and 4).

Locations

Country	Name	City	State
Taiwan	National Taiwan University Hospital	Taipei

Sponsors (2)

Lead Sponsor	Collaborator
National Taiwan University Hospital	The Industrial Technology Research Institute

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants with Adverse events (AEs) and serious AEs	Adverse events (AEs) and serious AEs	Baseline to Visit 7 (15th week)
Secondary	Western Ontario and McMaster Universities Index for osteoarthritis	Change in Western Ontario and McMaster Universities (WOMAC) Index for osteoarthritis: five items for pain (score range 0-20), two for stiffness (score range 0-8), and 17 for functional limitation (score range 0-68). Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.	Baseline to Visit 7 (15th week)
Secondary	Kellgren-Lawrence grading scale	Change in the Kellgren-Lawrence (KL) Grading Scale: 0-IV (0: normal, IV: the worst)	Baseline to Visit 7 (15th week)